Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Alamar Biosciences, Inc.NASDAQ: ALMR
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA of -$11.93M in Q2 FY2026
Q2 FY2026 EBITDA was -$11.93M.
Context
- EBITDA amounted to 33.5% of revenue in FY2025.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$37.98M (-52.6%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$11.93M+38.7% QoQ
- Last fiscal yearDec 2025
- -$24.89M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -52.6% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (24.89M) USD
- Year-over-year change
- —
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.89M) | — |
EBITDA vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's FY2025 EBITDA of -$24.89M is the 3rd highest of the 9 companies compared; the peer median is -$72.93M.
- EBITDA amounts to 33.5% of revenue for ALMR, versus a peer median of 66.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $328.77M | +48.3% | -9.1% | 26.8% | |
| LTM Sep 2026 | $37.56M | +221.9% | — | 6.1% | |
ALMRAlamar Biosciences, Inc. | FY2025 | -$24.89M | — | — | 33.5% |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$64.35M | +18.9% | — | 427.9% | |
| LTM Mar 2026 | -$81.51M | +5.7% | — | 94.5% | |
| LTM Mar 2026 | -$99.13M | -3.1% | — | 5352.8% | |
| LTM Mar 2026 | -$106.6M | +54.1% | — | 66.6% | |
| LTM Sep 2026 | -$129.8M | -149.9% | — | 28.3% | |
| Peer median (excluding ALMR) | -$72.93M | +15.3% | -9.1% | 66.6% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 74.21M |
| Cost of Revenue | 32.51M |
| Gross Profit | 41.71M |
| Gross Margin | 56.2% |
| Research & Development | 37.47M |
| Selling, General & Admin | 35.57M |
| Operating Expenses | 73.04M |
| Depreciation & Amortization | 3.86M |
| EBITDA | (24.89M) |
| EBITDA Margin | -33.5% |
| Operating Income | (31.33M) |
| Operating Margin | -42.2% |
| Interest Income | 2.16M |
| Interest Expense | 401K |
| Other Income / Expenses | 2.18M |
| Income Before Tax | (29.15M) |
| Pre-Tax Margin | -39.3% |
| Income Tax Expense | 665K |
| Net Income | (29.82M) |
| Net Margin | -40.2% |
| EPS (Basic) | (0.45) |
| EPS (Diluted) | (0.45) |
| Weighted Avg Shares | 66.52M |
| Weighted Avg Shares (Diluted) | 66.52M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.